New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 29, 2014
08:11 EDTGHDXGenomic Health's Oncotype DX colon cancer survey shows positive impact
Genomic Health announced results from the Oncotype DX colon cancer test studies highlighting the body of clinical evidence for the Oncotype DX colon cancer test and its real-life impact on patient and physician treatment decisions. Through an analysis of physician recommendations and patient treatment preferences before and after receiving the Oncotype DX colon cancer test results, this study demonstrated that the test increased concordance between physician and patient treatment choice from 66% to 96%, that the quantitative information provided by the Recurrence Score result influenced a majority of patients' treatment decisions and physicians' treatment recommendations, and increased physicians' confidence in their own recommendations. Patients' anxiety was also significantly reduced, which may improve adherence to their treatment plan and ultimately lead to better health outcomes.
News For GHDX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 28, 2015
05:21 EDTGHDXGenomic Health announces results from two studies for Oncotype DX
Genomic Health announced that, in addition to the positive five-year results from a group of patients with low Oncotype DX Recurrence Score results from the watershed ECOG-ACRIN Cancer Research Group's TAILORx study, sponsored by the National Cancer Institute, published in The New England Journal of Medicine, two additional positive international Oncotype DX clinical outcomes studies were presented at the 2015 European Cancer Congress. Together, these new studies establish Oncotype DX as the only genomic breast cancer test with prospective outcomes data in more than 5,700 patients to date, providing evidence that the biology information from the test should be included in treatment decisions. Reinforcing the published findings from TAILORx, two additional Oncotype DX clinical outcomes studies included positive results from a large, multi-center cohort from Clalit Health Services in Israel with follow-up exceeding 5 years, and a separate study of prospective survival results from the WSG Phase III Plan B trial in Germany.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use